Israel's High-Tech Catch-Up Process: The Role of IPR and Other Policies

Meir Pugatch, Morris Teubal, Odeda Zlotnick

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


This chapter discusses the experience of Israel. At the time of its independence in 1948, its people came from different parts of the world, providing them with international orientation from the beginning. As a result, many of the businesses targeted foreign markets, mainly USA and Europe, and were more concerned with the intellectual property regime in these foreign countries than Israel's own. Together with public support for innovation and military-related expenditure, some startup firms, mainly in information technologies, grew and succeeded in IPO (initial public offering) or selling themselves. Another successful case is Teva, now the largest generic drug producer. It benefited from the patent law amendment in 1967, which allowed local firms to copy patented drugs if the patent owners did not market them in Israel. This provision was dropped after TRIPS; however, Teva had accumulated process technologies by then.

Original languageEnglish
Title of host publicationIntellectual Property Rights, Development, and Catch-Up
Subtitle of host publicationAn International Comparative Study
PublisherOxford University Press
ISBN (Electronic)9780191722660
ISBN (Print)9780199574759
StatePublished - 1 May 2010

Bibliographical note

Publisher Copyright:
©Oxford University Press, 2013.


  • Drug
  • Generic
  • IPO
  • Information technology
  • Innovation
  • Intellectual property
  • Israel
  • Patent
  • Start-up

ASJC Scopus subject areas

  • General Business, Management and Accounting


Dive into the research topics of 'Israel's High-Tech Catch-Up Process: The Role of IPR and Other Policies'. Together they form a unique fingerprint.

Cite this